Abbott Labs must face lawsuit over PediaSure height claims

"The existence of studies contradicting the label's claim reinforce the plausibility of the complaint's allegation that the label would mislead a reasonable consumer," Engelmayer wrote.;

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-02-06 09:30 GMT | Update On 2024-03-22 08:56 GMT

New York: A judge has rejected Abbott Laboratories effort to dismiss a New York City grandmother's lawsuit claiming it misled consumers into believing its PediaSure Grow & Gain nutrition drinks were "clinically proven" to help children grow taller.

U.S. District Judge Paul Engelmayer in Manhattan said on Friday that Joanne Noriega's complaint set forth "strong, evidence-backed reasons" to doubt Abbott's claim that clinical studies supported its marketing claims.

Noriega cited three studies funded by Abbott itself that found no connection between PediaSure and growth in height.

"The existence of studies contradicting the label's claim reinforce the plausibility of the complaint's allegation that the label would mislead a reasonable consumer," Engelmayer wrote.

"This case is without merit," Abbott said in a statement on Saturday, adding that PediaSure is a scientifically designed nutrition solution for children to help support growth and development.

Noriega, from Bronx, New York, said she had bought PediaSure Grow & Gain vanilla and strawberry drinks for her 8-year-old grandson, who was "short for his age," believing they would help him get taller. She said that after a year of drinking two PediaSure drinks per day, her grandson was still short but had become "so overweight" that she stopped buying the drinks.

James Denlea, a lawyer for Noriega, said in an interview he was pleased with the decision, which lets his client gather more evidence through the discovery process.

Abbott had access to studies that "completely debunked any notion that its milkshake could help children grow," Denlea said. "The marketing was misleading, and Abbott knew that to be the case."

The lawsuit seeks unspecified damages for New Yorkers who were deceived into buying or overpaying for PediaSure.

Abbott has said PediaSure is intended for children ages 2 to 13, and helps them "grow out of at-risk weight-for-height percentiles (5th-25th percentiles)" within eight weeks.

PediaSure is part of the Abbott Park, Illinois-based company's pediatric nutritional segment, which also includes Pedialyte and Similac.

The case is Noriega v Abbott Laboratories, U.S. District Court, Southern District of New York, No. 23-04014.

Original news source: https://www.reuters.com/legal/abbott-labs-must-face-lawsuit-over-pediasure-height-claims-2024-02-02/

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Abbott Labs must face lawsuit over PediaSure height claims

"The existence of studies contradicting the label's claim reinforce the plausibility of the complaint's allegation that the label would mislead a reasonable consumer," Engelmayer wrote.;

Similar News

Merck receives positive EU CHMP opinion for Enflonsia for RSV in infants

Chennai Pharma Firm Under ED Net in Rs 637 Crore Bank Fraud Case

Biocon Gets CDSCO Panel Nod to Import Aflibercept Injection for Eye Disorders, Phase IV Trial Mandated

94 Drug, Medical Product Batches Fail CDSCO Quality Tests in August

Roche subcutaneous formulation of Lunsumio recommended by CHMP for EU nod for follicular lymphoma

Bayer new drug application for gadoquatrane accepted for review in China

JnJ gets positive CHMP opinion of nipocalimab for antibody-positive patients living with generalised myasthenia gravis

Allahabad HC Grants Relief to Pharma Firm Against Tax Notices